or Try an Advanced Search...

    Protein Kinase Inhibitor Stocks List

    Symbol Grade Name % Change
    DCPH A Deciphera Pharmaceuticals, Inc. 0.12
    BPMC B Blueprint Medicines Corporation -3.32
    ELVN B Enliven Therapeutics, Inc. -6.69
    GTHX B G1 Therapeutics, Inc. -2.27
    DAWN C Day One Biopharmaceuticals, Inc. 4.56
    CRIS C Curis, Inc. -0.10
    COGT C Cogent Biosciences, Inc. 1.12
    BBIO D BridgeBio Pharma, Inc. 0.98
    PBYI D Puma Biotechnology Inc -2.60
    PRLD D Prelude Therapeutics Incorporated -5.19
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Biopharmaceutical Tyrosine Kinase Receptors Tyrosine Kinase Breast Cancer Drugs Gastrointestinal Gastrointestinal Stromal Tumor Her2 Mastocytosis Systemic Mastocytosis Treatment Of Breast Cancer Biotechnology Blastoma Clinical Development Enzymes Fibroblast Growth Factor Receptor Gastrointestinal Stromal Tumors Glioblastoma Glioblastoma Multiforme

    Related ETFs - A few ETFs which own one or more of the above listed Protein Kinase Inhibitor stocks.

    Symbol Grade Name Weight
    IDNA C iShares Genomics Immunology and Healthcare ETF 3.33
    LABD D Direxion Daily S&P Biotech Bear 3X Shares 2.98
    FBT D First Trust Amex Biotech Index Fund 2.87
    PBE C PowerShares Dynamic Biotech & Genome 2.7
    CNCR D Loncar Cancer Immunotherapy ETF 2.48
    View all Protein Kinase Inhibitor ETFs...
    Compare ETFs
    Compare FBT to PBE Compare IDNA to LABD Compare IDNA to PBE

        Protein Kinase Inhibitor Stocks Recent News

        Date Stock Title
        Jun 3 PRLD Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
        Jun 3 DCPH Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
        Jun 2 PBYI Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
        May 31 GTHX G1 Therapeutics (NASDAQ:GTHX shareholders incur further losses as stock declines 19% this week, taking three-year losses to 84%
        May 30 BPMC Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
        May 30 PRLD Prelude Therapeutics files for $400M mixed securities shelf
        May 30 DAWN Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
        May 30 DAWN Day One Announces Sale of Priority Review Voucher for $108 Million
        May 29 BBIO BridgeBio reports additional positive data for acoramidis in ATTR-CM
        May 29 ELVN Enliven Therapeutics to Present at Two Upcoming Investor Conferences
        May 29 BBIO Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
        May 28 GTHX G1 Therapeutics slips after new breast cancer data for lead asset
        May 28 PBYI Puma Biotechnology to join Russell 3000 Index
        May 28 PBYI Puma Biotechnology to Join Russell 3000 Index
        May 28 GTHX Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Biopharmaceutical Biotechnology Breast Cancer Her2 Her2/Neu Small Molecule Therapies Treatment Of Breast Cancer Treatment Of Cancer Tyrosine Kinase Tyrosine Kinase Receptors Acute Myeloid Leukemia Advanced Breast Cancer Advanced Cancer Antiestrogens Blastoma Cancer Treatment Chemical Compounds Chloroarenes Chronic Myeloid Leukemia
        Protein Kinase Inhibitor

        Protein kinase inhibitors are drugs that block the activity of one or more protein kinases. Protein kinases are enzymes that add phosphate groups to proteins, which can alter their activity and function. Protein kinase inhibitors are used to treat a variety of diseases, including cancer, inflammation, and autoimmune disorders.

        Browse All Tags